Lundbeck Discontinues Phase 2 Study of Lu AF11167 in Patients with Schizophrenia

Lundbeck Discontinues Phase 2 Study of Lu AF11167 in Patients with Schizophrenia

Lundbeck announced a decision to discontinue a phase II proof of concept clinical study of Lu AF11167 in patients with schizophrenia who are experiencing persistent negative symptoms. The decision to stop the trial is based on the results of a futility interim analysis, which concluded that the trial is unlikely to achieve statistical significance on its primary endpoint, mean change from baseline to week 12 on the Brief Negative Symptom Scale (BNSS). The recommendation to stop the trial is not based on safety concerns. Lundbeck plans to submit the study results for scientific publication at a later date.

The primary objective of the phase II study was to evaluate the efficacy of negative symptoms of two doses of Lu AF11167 versus placebo as monotherapy in patients with schizophrenia and persistent, prominent negative symptoms. The secondary objective was to evaluate the efficacy of Lu AF11167 on patients’ functioning and the safety and tolerability of the compound. This 3-arm study was planned to randomize 240 patients (80 patients per arm) from various European countries.

About Lu AF11167

Lu AF11167 is a small molecule and a potent and selective inhibitor...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee